A study evaluating the effects of 161 different kinase inhibitors on melanoma cell lines found that regorafenib is the only drug that reduces the expression of PD-L1 in tumor cells without decreasing the amount of MHC-I on the surface of the cell (116). Here, CD274 is linked to neoplasm.